[HTML][HTML] RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, epidermal growth factor receptor mutation-positive, metastatic non …
Introduction RELAY was a global, double-blind, placebo-controlled phase III study that
demonstrated superior progression-free survival (PFS) for ramucirumab plus erlotinib …
demonstrated superior progression-free survival (PFS) for ramucirumab plus erlotinib …
Ramucirumab or placebo plus erlotinib in EGFR‐mutated, metastatic non‐small‐cell lung cancer: East Asian subset of RELAY
M Nishio, T Seto, M Reck, EB Garon, CH Chiu… - Cancer …, 2020 - Wiley Online Library
In the global phase III RELAY study, ramucirumab plus erlotinib (RAM+ ERL) demonstrated
superior progression‐free survival (PFS) to placebo plus erlotinib (PL+ ERL) in untreated …
superior progression‐free survival (PFS) to placebo plus erlotinib (PL+ ERL) in untreated …
[HTML][HTML] RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in patients with untreated, EGFR-mutated, metastatic non-small cell lung cancer: Europe …
SP Aix, S Novello, EB Garon, K Nakagawa… - Cancer Treatment and …, 2021 - Elsevier
Background In EGFR mutation-positive NSCLC, dual EGFR/VEGFR inhibition compared to
EGFR alone increases anti-tumor efficacy. The Phase III RELAY trial demonstrated superior …
EGFR alone increases anti-tumor efficacy. The Phase III RELAY trial demonstrated superior …
[HTML][HTML] RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response …
K Nakagawa, EB Garon, L Gao, S Callies… - Cancer chemotherapy …, 2022 - Springer
Purpose In RELAY, ramucirumab plus erlotinib (RAM+ ERL) improved progression-free
survival (PFS) in patients with untreated, metastatic, EGFR-mutated, non-small cell lung …
survival (PFS) in patients with untreated, metastatic, EGFR-mutated, non-small cell lung …
[HTML][HTML] Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small …
CH Chiu, MC Lin, YF Wei, GC Chang, WC Su… - Targeted Oncology, 2023 - Springer
Background In RELAY, a randomized, double-blind, phase III trial investigating the efficacy
and safety of ramucirumab+ erlotinib (RAM+ ERL) or ERL+ placebo (PBO) in patients with …
and safety of ramucirumab+ erlotinib (RAM+ ERL) or ERL+ placebo (PBO) in patients with …
Patient-reported outcomes in RELAY, a phase 3 trial of ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small-cell …
K Yoh, S Atagi, M Reck, EB Garon… - Current Medical …, 2020 - Taylor & Francis
Objective In the phase 3 RELAY trial, ramucirumab/erlotinib demonstrated superior
progression-free survival (PFS) over placebo/erlotinib in patients with EGFR-mutated …
progression-free survival (PFS) over placebo/erlotinib in patients with EGFR-mutated …
RELAY+: Exploratory study of ramucirumab plus gefitinib in untreated patients (pts) with epidermal growth factor receptor (EGFR)-mutated metastatic non-small cell …
9564 Background: The phase III randomized part of the RELAY study (Part B; RELAY;
NCT02411448) showed a significant improvement in progression-free survival (PFS) for …
NCT02411448) showed a significant improvement in progression-free survival (PFS) for …
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled …
K Nakagawa, EB Garon, T Seto, M Nishio… - The Lancet …, 2019 - thelancet.com
Background Dual blockade of the EGFR and VEGF pathways in EGFR-mutated metastatic
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
non-small-cell lung cancer (NSCLC) is supported by preclinical and clinical data, yet the …
RELAY: A multinational, double-blind, randomized Phase 3 study of erlotinib (ERL) in combination with ramucirumab (RAM) or placebo (PL) in previously untreated …
K Nakagawa, EB Garon, T Seto, M Nishio, S Ponce Aix… - 2019 - ascopubs.org
9000 Background: Dual blockade of EGFR and VEGFR pathways in EGFRm NSCLC
augments anti-tumor efficacy versus (v) EGFR inhibition alone. RELAY (NCT02411448) …
augments anti-tumor efficacy versus (v) EGFR inhibition alone. RELAY (NCT02411448) …
Treatment rationale and study design for the RELAY study: a multicenter, randomized, double-blind study of erlotinib with ramucirumab or placebo in patients with …
EB Garon, M Reck, L Paz-Ares, S Ponce, JC Jaime… - Clinical lung …, 2017 - Elsevier
Introduction We present the treatment rationale and study design for the RELAY study
(NCT02411448). This phase Ib/III study will assess safety, tolerability, and efficacy of the …
(NCT02411448). This phase Ib/III study will assess safety, tolerability, and efficacy of the …